I aim to get baseline data on the frequency of high-risk BRCA I & II mutations in archived FFPE ovarian serous cystadenocarcinoma in the Pathology department.
Well, Dr Halima Aliyu, thank you for your question. Kindly read a bit my answer to your questions. I think you may find it helpful. See below:-
The most commonly used techniques are the single-strand conformation polymorphism (SSCP), restriction endonuclease fingerprinting (REF)-SSCP, conformation-sensitive gel electrophoresis (CSGE), fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE), two-dimensional gene scanning (TDGS), protein truncation test (PTT), and denaturing high-performance liquid chromatography (DHPLC). The first five methods are based on the different motility of the mutant DNA fragment. PTT is an in vitro transcription–translation assay for the detection of truncating mutations. DHPLC uses chromatography to separate hetero- from homoduplices under high pressure and partially denaturing temperature conditions. Numerous other methods have been developed for the detection of sequence alterations. These include the restriction enzyme-based techniques enzymatic mutation detection (EMD) and multiple-dye cleavase fragment length polymorphism (MD-CFLP), the yeast-based stop codon (SC) assay, which detects truncating mutations and requires RNA, RNA-based sequencing, the micronucleus test (MNT), originally established to determine DNA damage. Recently, there have been reports on further techniques for the detection of BRCA1 and BRCA2 mutations, namely a real-time PCR-based approach using sequence-specific probes, the array-based chip technology using SNP-specific oligonucleotides, and MALDI-TOF mass spectrometry.
Wishing you all the best my sister. In case, you might need more information, I will attached some papers to you regarding these techniques. I wish your department in ABU can buy all the facilities that will be required to run this experimental assays.